Baillie Gifford & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Baillie Gifford & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-193	Closed	-$28.2K	–	368
2023 Q1	$28.2K	Buy	193 +25	+15%	+$3.7K	﹤0.01%	316
2022 Q4	$26.8K	Hold	168	–	–	﹤0.01%	322
2022 Q3	$22K	Hold	168	–	–	﹤0.01%	321
2022 Q2	$26K	Buy	168 +3	+2%	+$462	﹤0.01%	319
2022 Q1	$26K	Hold	165	–	–	﹤0.01%	335
2021 Q4	$21K	Buy	+165	New	+$21.7K	﹤0.01%	370

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Baillie Gifford & Co's JAZZ Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 193 shares — an estimated $28.2K sold.

Baillie Gifford & Co first reported a position in JAZZ in Q4 2021 and held it in 6 quarters. The position peaked at $28.2K in Q1 2023. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Baillie Gifford & Co reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Baillie Gifford & Co sold 193 Jazz Pharmaceuticals shares in Q2 2023, an estimated $28.2K.
Baillie Gifford & Co first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Baillie Gifford & Co's Jazz Pharmaceuticals position peaked at $28.2K in Q1 2023.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.